Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Cancer Res. 2021 Jun 9;81(17):4373–4384. doi: 10.1158/0008-5472.CAN-21-0301

Figure 1: 60 years young: the history of allogeneic HSCT.

Figure 1:

Timeline summarizing major milestones in the history of allo-HSCT. HLA: human leukocyte antigen; DLI: donor lymphocyte infusion; mHAg: minor histocompatibility antigen; CAR: chimeric antigen receptor; TCR: T cell receptor.